Anti-IDH2 (mutation R172H) Monoclonal Antibody, clone XH070

Name: Anti-IDH2 (mutation R172H) Monoclonal Antibody, clone XH070
SKU: DMAB-DCC064
Rating: 5 (1 reviews)

Mouse Anti-Human IDH2 (mutation R172H) Monoclonal Antibody for ELISA, WB, IHC, IF

COA

SDS

Datasheet

Summary

Specifications

Antibody Isotype

IgG

Clone

XH070

Species Reactivity

Human

Immunogen

A synthetic peptide from the internal region of human IDH2 which includes the mutation of R172H.

Conjugate

Unconjugated

Applications

Application Notes

ELISA: 1:1000-1:5000
WB: 1:100-1:1000
IHC: 1:50-1:100

Target

Entrez Gene ID

3418

UniProt ID

B4DFL2

Product Background

Antigen Description

Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutations of Arg-172 in IDH2 to Cys, His, Leu or Ser abolish magnesium binding and the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R-2-hydroxyglutarate. Elevated levels of R-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.

Pathway

2-Oxocarboxylic acid metabolism; Biosynthesis of amino acids; Carbon metabolism; Citrate cycle (TCA cycle)

Citations

Have you cited DMAB-DCC064 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

IDH2 inhibition: another piece to the puzzle

BLOOD

Authors: Bullinger, Lars

Abstract

In this issue of Blood, Stein et al(1) report the outcomes for all isocitrate dehydrogenase-2 (IDH2) mutant relapsed or refractory acute myeloid leukemia (R/R AML) patients treated with enasidenib in the first phase 1/2 study including data on molecular clearance and molecular relationships to response or resistance.

Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1

LEUKEMIA & LYMPHOMA

Authors: Nguyen, Lynh; Zhang, Xiaohui; Roberts, Evans; Yun, Seongseok; McGraw, Kathy; Abraham, Ivo; Song, Jinming; Braswell, Diana; Qin, Dahui; Sallman, David A.; Lancet, Jeffrey E.; List, Alan F.; Moscinski, Lynn C.; Padron, Eric; Zhang, Ling

Abstract

Studies comparing the prognostic role of RUNX1 mutations (RUNX1(mut)) in acute myeloid leukemia (AML) and acute myeloid leukemia-with myelodysplasia-related changes (AML-MRC) are limited. Our study examines the genetic profile of 118 RUNX1(mut) AML patients including 57 AML with RUNX1(mut) and 61 AML-MRC with RUNX1(mut) and 100 AML, NOS patients with wild type RUNX1 (RUNX1(wt)). Results revealed that AML-MRC patients with RUNX1(mut) had shorter median overall survival (OS) (11 +/- 3.3 months) when compared to AML with RUNX1(mut) (19 +/- 7.1 months) and AML, NOS with RUNX1(wt) (not reached) (p = .001). The most common concurrent mutations observed in AML-MRC with RUNX1(mut) patients were DNMT3A, SRSF2, ASXL1, and IDH2 while in AML with RUNX1(mut) patients were ASXL1, SRSF2, TET2, IDH2, and DNMT3A. ASXL1 and TET2 mutations appeared to adversely affect OS in AML-MRC, but not in AML with RUNX1(mut). Concurrent RUNX1/DNMT3A mutations, in contrast had negative impact on OS in AML with RUNX1(mut), but not in AML-MRC with RUNX1(mut).